Analyst Price Targets — INCY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 18, 2026 10:10 am | — | Barclays | $117.00 | $101.16 | TheFly | Incyte price target raised to $117 from $116 at Barclays |
| February 11, 2026 2:09 pm | — | Morgan Stanley | $102.00 | $98.45 | TheFly | Incyte price target raised to $102 from $94 at Morgan Stanley |
| February 11, 2026 12:14 pm | Stephen Willey | Stifel Nicolaus | $120.00 | $100.05 | TheFly | Incyte price target raised to $120 from $119 at Stifel |
| February 6, 2026 11:52 am | Allison Bratzel | Piper Sandler | $110.00 | $102.76 | TheFly | Incyte price target raised to $110 from $102 at Piper Sandler |
| February 5, 2026 11:05 am | — | H.C. Wainwright | $135.00 | $102.60 | TheFly | Incyte initiated with a Buy at H.C. Wainwright |
| February 4, 2026 10:46 am | — | Barclays | $116.00 | $100.92 | TheFly | Incyte price target raised to $116 from $115 at Barclays |
| January 20, 2026 10:19 am | — | Wells Fargo | $107.00 | $106.21 | TheFly | Incyte downgraded to Equal Weight from Overweight at Wells Fargo |
| January 8, 2026 12:39 pm | — | Goldman Sachs | $90.00 | $110.57 | TheFly | Incyte price target raised to $90 from $80 at Goldman Sachs |
| January 5, 2026 6:33 pm | Stephen Willey | Stifel Nicolaus | $119.00 | $101.79 | StreetInsider | Stifel Reiterates Buy Rating on Incyte (INCY) |
| December 24, 2025 12:08 pm | Srikripa Devarakonda | Truist Financial | $103.00 | $100.91 | TheFly | Incyte price target raised to $103 from $93 at Truist |
Latest News for INCY
Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeks The study is the first and largest of its kind specifically designed to evaluate children and adolescents with severe AA, a disease that has devastating social and emotional impact Lilly has also submitted Olumiant in the U.S. for…
Andra AP fonden lifted its holdings in shares of Incyte Corporation (NASDAQ: INCY) by 24.2% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 460,600 shares of the biopharmaceutical company's stock after buying an additional 89,800 shares during the period.
Citigroup Inc. grew its position in Incyte Corporation (NASDAQ: INCY) by 187.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 560,028 shares of the biopharmaceutical company's stock after buying an additional 364,946 shares during the quarter.
Aberdeen Group plc lifted its position in Incyte Corporation (NASDAQ: INCY) by 24.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 147,411 shares of the biopharmaceutical company's stock after acquiring an additional 28,734 shares during the period. Aberdeen Group
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.